Viral Hepatitis C: From Unraveling the Nature of Disease to Cure and Global Elimination.

IF 2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Digestive Diseases Pub Date : 2024-05-08 DOI:10.1159/000539210
Viktorija Basyte-Bacevice, Limas Kupcinskas
{"title":"Viral Hepatitis C: From Unraveling the Nature of Disease to Cure and Global Elimination.","authors":"Viktorija Basyte-Bacevice, Limas Kupcinskas","doi":"10.1159/000539210","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The discovery of the hepatitis C virus (HCV) and direct-acting antiviral (DAA) drugs is one of the major milestones in the last 3 decades of medicine. These discoveries encouraged the World Health Organization (WHO) to set an ambitious goal to eliminate HCV by 2030, meaning \"a 90% reduction in new cases of chronic HCV, a 65% reduction in HCV deaths, and treatment of 80% of eligible people with HCV infections.\"</p><p><strong>Summary: </strong>This review summarizes the key achievements from the discovery of HCV to the development of effective treatment and global elimination strategies. A better understanding of HCV structure, enzymes, and lifecycle led to the introduction of new drug targets and the discovery of DAA. Massive public health interventions are required, such as screening, access to care, treatment, and post-care follow-up, to make the most of DAA's potential. Screening must be supported by fast, accessible, sensitive, specific HCV diagnostic tests and noninvasive methods to determine the stage of liver disease. Linkage to care and treatment access are critical components of a comprehensive HCV elimination program, and decentralization plays a key role in ensuring their effectiveness.</p><p><strong>Key messages: </strong>Effective and simple screening strategies, rapid diagnostic tools, linkage to health care, and accessible treatment are key elements to achieving the WHO's goal. Incorporating treatment as prevention strategies into elimination programs together with preventive education and harm reduction interventions can have a profound and lasting impact on reducing both the incidence and prevalence of HCV. However, WHO's goal can be challenging to implement because of the need for high financial resources and strong political commitment.</p>","PeriodicalId":11294,"journal":{"name":"Digestive Diseases","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000539210","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The discovery of the hepatitis C virus (HCV) and direct-acting antiviral (DAA) drugs is one of the major milestones in the last 3 decades of medicine. These discoveries encouraged the World Health Organization (WHO) to set an ambitious goal to eliminate HCV by 2030, meaning "a 90% reduction in new cases of chronic HCV, a 65% reduction in HCV deaths, and treatment of 80% of eligible people with HCV infections."

Summary: This review summarizes the key achievements from the discovery of HCV to the development of effective treatment and global elimination strategies. A better understanding of HCV structure, enzymes, and lifecycle led to the introduction of new drug targets and the discovery of DAA. Massive public health interventions are required, such as screening, access to care, treatment, and post-care follow-up, to make the most of DAA's potential. Screening must be supported by fast, accessible, sensitive, specific HCV diagnostic tests and noninvasive methods to determine the stage of liver disease. Linkage to care and treatment access are critical components of a comprehensive HCV elimination program, and decentralization plays a key role in ensuring their effectiveness.

Key messages: Effective and simple screening strategies, rapid diagnostic tools, linkage to health care, and accessible treatment are key elements to achieving the WHO's goal. Incorporating treatment as prevention strategies into elimination programs together with preventive education and harm reduction interventions can have a profound and lasting impact on reducing both the incidence and prevalence of HCV. However, WHO's goal can be challenging to implement because of the need for high financial resources and strong political commitment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
丙型病毒性肝炎:从揭示疾病本质到治愈和全球消除。
本综述总结了从发现丙型肝炎病毒到开发有效治疗方法和全球消除战略的主要成就。由于对HCV结构、酶和生命周期有了更深入的了解,因此引入了新的药物靶点,并发现了DAA。为了最大限度地发挥 DAA 的潜力,需要采取大规模的公共卫生干预措施,如筛查、获得护理、治疗和护理后随访。筛查工作必须得到快速、便捷、灵敏、特异的 HCV 诊断测试和非侵入性方法的支持,以确定肝病的阶段。护理链接和治疗途径是全面消除 HCV 计划的关键组成部分,而权力下放在确保其有效性方面发挥着关键作用。关键信息:有效而简单的筛查策略、快速诊断工具、联系医疗保健和获得治疗是实现世卫组织目标的关键因素。将治疗作为预防战略纳入消除计划,同时开展预防教育和减少危害干预措施,可对降低丙型肝炎病毒的发病率和流行率产生深远而持久的影响。然而,由于需要大量财政资源和强有力的政治承诺,世卫组织目标的实施可能具有挑战性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Digestive Diseases
Digestive Diseases 医学-胃肠肝病学
CiteScore
4.80
自引率
0.00%
发文量
58
审稿时长
2 months
期刊介绍: Each issue of this journal is dedicated to a special topic of current interest, covering both clinical and basic science topics in gastrointestinal function and disorders. The contents of each issue are comprehensive and reflect the state of the art, featuring editorials, reviews, mini reviews and original papers. These individual contributions encompass a variety of disciplines including all fields of gastroenterology. ''Digestive Diseases'' bridges the communication gap between advances made in the academic setting and their application in patient care. The journal is a valuable service for clinicians, specialists and physicians-in-training.
期刊最新文献
Esophageal varices as an independent predictor of fatal outcomes after balloon-occluded retrograde transvenous obliteration in patients with hepatic encephalopathy. Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial. Prevalence of Helminth Infections in Patients with Celiac Disease. Adverse Events after Different Endoscopic Resection Procedures for Small and Intermediate-Sized Colorectal Polyps. Is Cholecystectomy Necessary after Choledocholithiasis Treatment for the Elderly or Patients with Many Comorbidities?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1